GlassScriptPhysician profile
Thaddeo C Oconer
NPI 1104928571
$2,629.63
in general payments reported to CMS, 2019-2025
30 companies · $639 in 2025
The $639 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $31.25 · 2021: $253 · 2022: $409 · 2023: $492 · 2024: $521 · 2025: $639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,583 · Education: $68.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,582.87 |
| Education | $68.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $472.77 | 2019-2025 | Krystexxa, Tavneos |
| Horizon Therapeutics Plc | $264.31 | 2019-2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $240.59 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $240.03 | 2019-2024 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $164.50 | 2019-2025 | Jynarque, Voyxact |
| Alexion Pharmaceuticals, INC. | $131.00 | 2022-2025 | Ultomiris |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $118.53 | 2022-2025 | Jynarque |
| Daiichi Sankyo INC. | $112.20 | 2020-2025 | Injectafer |
| Glaxosmithkline, LLC. | $111.37 | 2022-2025 | Benlysta, Jesduvroq, Arexvy |
| Novartis Pharmaceuticals Corporation | $93.57 | 2021-2025 | |
| Vifor Pharma, INC. | $84.26 | 2019-2023 | Veltassa |
| Janssen Pharmaceuticals, INC | $81.18 | 2019 | |
| Akebia Therapeutics INC | $59.98 | 2022-2025 | Vafseo |
| Kyowa Kirin, INC. | $54.76 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $42.50 | 2024 | Crysvita |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $42.04 | 2021-2023 | Lupkynis |
| Opko Pharmaceuticals, LLC | $37.12 | 2019-2021 | |
| Ardelyx, INC. | $35.13 | 2024-2025 | Ibsrela |
| Calliditas Therapeutics US INC. | $34.72 | 2022-2025 | Tarpeyo |
| Alnylam Pharmaceuticals INC. | $26.48 | 2023 | Givlaari |
| Mallinckrodt Enterprises LLC | $23.66 | 2019 | |
| Mallinckrodt Hospital Products INC. | $23.09 | 2024 | Acthar |
| Apellis Pharmaceuticals, INC. | $21.52 | 2025 | Empaveli |
| Recordati_rare_diseases_inc. | $20.93 | 2024 | Isturisa, Signifor Lar |
| Amicus Therapeutics, INC. | $17.71 | 2020 | |
| Chiesi USA, INC. | $16.96 | 2023 | Elfabrio |
| Arbor Pharmaceuticals, INC. | $15.42 | 2021 | |
| Shire North American Group INC | $15.16 | 2019 | |
| Strongbridge US INC. | $14.09 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thaddeo Oconer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.